Price Target Increase#
Evercore ISI has raised its price target for Elevance Health Inc. shares (NYSE:ELV) from $345 to $360. The firm maintains an 'In Line' rating on the stock, which currently trades at approximately $328.20. With a market capitalization of $72 billion, Elevance is considered undervalued according to recent analyses.
Earnings Performance#
In its latest earnings report, Elevance Health's first quarter results met expectations on an operating basis. While the overall results showed a positive surprise, adjustments for non-operating items indicated that the operating performance was in line. The adjusted earnings per share included contributions from net investment income and favorable prior year developments, although higher trends and a decline in enrollment at Carelon posed challenges.
Future Outlook#
Management's outlook for the rest of the year appears optimistic, with potential reserve releases estimated between $200 million and $400 million if current trends continue. This could add approximately 70 cents to $1.40 to earnings per share, further enhancing the company's financial standing.
Valuation Insights#
Evercore ISI has also raised its earnings per share estimate for Elevance for 2026 to $26.87 from $25.94. The company's price-to-earnings (P/E) ratio stands at 13.09, indicating an attractive valuation compared to its revenue valuation multiple. Recent financial results have exceeded analyst expectations, with an adjusted diluted EPS of $12.58, significantly higher than the forecasted $10.84. Revenue reached $49.5 billion, surpassing the anticipated $48.2 billion, reinforcing a positive outlook from the investment community.